• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Effect of probenecid on the elimination and protein binding of ceftriaxone.

作者信息

Stoeckel K, Trueb V, Dubach U C, McNamara P J

机构信息

Clinical Research Department F. Hoffmann-La Roche & Co. Ltd., Basel.

出版信息

Eur J Clin Pharmacol. 1988;34(2):151-6. doi: 10.1007/BF00614552.

DOI:10.1007/BF00614552
PMID:3383987
Abstract

The kinetics and binding parameters of ceftriaxone have been characterized in eight normal subjects who received, in sequence, 1.0 g ceftriaxone and 1.0 g ceftriaxone together with 250 and 500 mg probenecid q.i.d. Probenecid increased the total systemic clearance (CLTS) from 0.244 to 0.312 ml/min/kg, whereas the terminal half-life (t1/2T (beta)) fell from 8.1 to 6.5 h. In contrast, the renal clearance of free ceftriaxone (CLFR) was decreased from 2.09 to 1.67 ml/min/kg, confirming a small but significant contribution of tubular secretion to the renal elimination of ceftriaxone. The final value of CLFR was attained with the lower dose probenecid, whereas the non-renal clearance of free ceftriaxone (CLFNR) fell progressively from 2.78 to 1.90 ml/min/kg with the increasing probenecid dose. The total decrease in the systemic clearance of free ceftriaxone (CLFS) after the higher dose of probenecid was about 30% (4.87 to 3.57 ml/min/kg). As a consequence of a decreased affinity constant (KA), the average free fraction in plasma (f) was increased by 54% after the low dose and by 74% after the high dose of probenecid. The protein binding interaction between probenecid and ceftriaxone appears to be unique. The results are of limited clinical consequence for ceftriaxone but they emphasise the importance of evaluating the kinetics of the free drug when examining interactions involving probenecid.

摘要

相似文献

1
Effect of probenecid on the elimination and protein binding of ceftriaxone.
Eur J Clin Pharmacol. 1988;34(2):151-6. doi: 10.1007/BF00614552.
2
Effects of concentration-dependent plasma protein binding on ceftriaxone kinetics.浓度依赖性血浆蛋白结合对头孢曲松动力学的影响。
Clin Pharmacol Ther. 1981 May;29(5):650-7. doi: 10.1038/clpt.1981.90.
3
Lack of probenecid effect on nonrenal excretion of ceftriaxone in anephric patients.丙磺舒对无肾患者头孢曲松非肾排泄无影响。
J Clin Pharmacol. 1990 May;30(5):449-53. doi: 10.1002/j.1552-4604.1990.tb03484.x.
4
Physiologically based pharmacokinetic model for the renal clearance of iodopyracet and the interaction with probenecid in the dog.
Biopharm Drug Dispos. 1989 Mar-Apr;10(2):137-52. doi: 10.1002/bdd.2510100204.
5
Ceftriaxone binding to human serum albumin. Indirect displacement by probenecid and diazepam.头孢曲松与人血清白蛋白的结合。丙磺舒和地西泮的间接置换作用。
Biochem Pharmacol. 1990 Sep 15;40(6):1247-53. doi: 10.1016/0006-2952(90)90390-7.
6
Non-linear elimination and protein binding of probenecid.丙磺舒的非线性消除与蛋白结合
Eur J Clin Pharmacol. 1987;32(4):395-401. doi: 10.1007/BF00543976.
7
Single-dose ceftriaxone kinetics in the newborn.新生儿单剂量头孢曲松的动力学
Clin Pharmacol Ther. 1985 May;37(5):522-8. doi: 10.1038/clpt.1985.82.
8
The human pharmacokinetics of cefotaxime and its metabolites and the role of renal tubular secretion on their elimination.头孢噻肟及其代谢产物的人体药代动力学以及肾小管分泌在其消除过程中的作用。
J Pharmacokinet Biopharm. 1985 Apr;13(2):121-42. doi: 10.1007/BF01059394.
9
Disposition kinetics and dosage regimen of ceftriaxone in crossbred calves (short communication).头孢曲松在杂交犊牛中的处置动力学和给药方案(简报)
Acta Vet Hung. 1999;47(2):243-8. doi: 10.1556/004.47.1999.2.9.
10
Effects of probenecid on enprofylline kinetics in man.丙磺舒对人体中恩丙茶碱动力学的影响。
Eur J Clin Pharmacol. 1986;30(2):221-3. doi: 10.1007/BF00614308.

引用本文的文献

1
Comparison of the Pharmacokinetic Profiles of Ceftriaxone Used Alone and Combined with Danhong Injection in Old Rats.老年大鼠单独使用头孢曲松与联合丹红注射液的药代动力学特征比较
Eur J Drug Metab Pharmacokinet. 2019 Aug;44(4):505-517. doi: 10.1007/s13318-018-0530-6.
2
Renal Drug Transporters and Drug Interactions.肾脏药物转运体与药物相互作用
Clin Pharmacokinet. 2017 Aug;56(8):825-892. doi: 10.1007/s40262-017-0506-8.
3
Transporter-Mediated Disposition of Opioids: Implications for Clinical Drug Interactions.转运体介导的阿片类药物处置:对临床药物相互作用的影响

本文引用的文献

1
Pharmacokinetics of Rocephin, a highly active new cephalosporin with an exceptionally long biological half-life.头孢曲松(Rocephin)的药代动力学,一种具有超长生物半衰期的高活性新型头孢菌素。
Chemotherapy. 1981;27 Suppl 1:42-6. doi: 10.1159/000238028.
2
Pharmacokinetics of probenecid following oral doses to human volunteers.丙磺舒对人类志愿者口服给药后的药代动力学。
J Pharm Sci. 1982 Nov;71(11):1238-42. doi: 10.1002/jps.2600711114.
3
Effects of concentration-dependent plasma protein binding on ceftriaxone kinetics.浓度依赖性血浆蛋白结合对头孢曲松动力学的影响。
Pharm Res. 2015 Aug;32(8):2477-502. doi: 10.1007/s11095-015-1711-5. Epub 2015 May 14.
4
Assessment of the role of renal organic anion transporters in drug-induced nephrotoxicity.评估肾有机阴离子转运体在药物性肾毒性中的作用。
Toxins (Basel). 2010 Aug;2(8):2055-82. doi: 10.3390/toxins2082055. Epub 2010 Aug 9.
5
Cephalosporin-probenecid drug interactions.头孢菌素-丙磺舒药物相互作用。
Clin Pharmacokinet. 1993 Apr;24(4):289-300. doi: 10.2165/00003088-199324040-00003.
6
Ceftriaxone disposition in open-heart surgery patients.头孢曲松在心脏直视手术患者中的处置情况。
Antimicrob Agents Chemother. 1989 Jun;33(6):850-6. doi: 10.1128/AAC.33.6.850.
7
Protein binding drug displacement interactions fact or fiction?蛋白结合药物置换相互作用:事实还是虚构?
Clin Pharmacokinet. 1989 Feb;16(2):65-73. doi: 10.2165/00003088-198916020-00001.
8
No effect of probenecid on the renal and biliary clearances of digoxin in man.丙磺舒对人体地高辛肾清除率和胆汁清除率无影响。
Br J Clin Pharmacol. 1991 Jul;32(1):63-7. doi: 10.1111/j.1365-2125.1991.tb05614.x.
9
Direct measurement of probenecid and its glucuronide conjugate by means of high pressure liquid chromatography in plasma and urine of humans.通过高压液相色谱法直接测定人体血浆和尿液中丙磺舒及其葡糖醛酸共轭物。
Pharm Weekbl Sci. 1992 Jun 19;14(3):83-7. doi: 10.1007/BF01962691.
10
Capacity-limited renal glucuronidation of probenecid by humans. A pilot Vmax-finding study.人体对丙磺舒的肾葡萄糖醛酸化能力受限。一项初步的最大反应速度(Vmax)探索性研究。
Pharm Weekbl Sci. 1992 Oct 16;14(5):325-31. doi: 10.1007/BF01977622.
Clin Pharmacol Ther. 1981 May;29(5):650-7. doi: 10.1038/clpt.1981.90.
4
Clinical pharmacokinetics of probenecid.丙磺舒的临床药代动力学。
Clin Pharmacokinet. 1981 Mar-Apr;6(2):135-51. doi: 10.2165/00003088-198106020-00004.
5
Ro 13-9904, a long-acting broad-spectrum cephalosporin: in vitro and in vivo studies.Ro 13-9904,一种长效广谱头孢菌素:体外和体内研究
Antimicrob Agents Chemother. 1980 Dec;18(6):913-21. doi: 10.1128/AAC.18.6.913.
6
Interaction of probenecid with the protein binding of methotrexate.丙磺舒与甲氨蝶呤蛋白结合的相互作用。
Pharmacology. 1984;28(2):86-9. doi: 10.1159/000137947.
7
Volume of distribution terms for a drug (ceftriaxone) exhibiting concentration-dependent protein binding. I. Theoretical considerations.具有浓度依赖性蛋白结合特性的药物(头孢曲松)的分布容积术语。I. 理论考量。
Eur J Clin Pharmacol. 1983;25(3):399-405. doi: 10.1007/BF01037955.
8
Effect of ceftizoxime, a new cephalosporin antibiotic, on binding of bilirubin to human serum albumin.新型头孢菌素抗生素头孢唑肟对胆红素与人血清白蛋白结合的影响。
Chemotherapy. 1983;29(4):244-8. doi: 10.1159/000238205.
9
Single-dose ceftriaxone kinetics in functionally anephric patients.功能无肾患者的单剂量头孢曲松动力学
Clin Pharmacol Ther. 1983 May;33(5):633-41. doi: 10.1038/clpt.1983.86.
10
Pharmacokinetics of ceftriaxone following intravenous administration of a 3 g dose.静脉注射3克剂量头孢曲松后的药代动力学。
Eur J Clin Pharmacol. 1982;22(1):71-5. doi: 10.1007/BF00606428.